Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Netherlands-based biopharmaceutical company OctoPlus has signed a new drug delivery technology evaluation contract with a European biotechnology company as part of the company's strategic focus on developing controlled release formulations for clients.
Subscribe to our email newsletter
In October 2008, OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.
Under the terms of the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’s drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.